Biocon Biologics, a subsidiary of Biocon has announced that Hulio (adalimumab-fkjp) injection, a biosimilar to Humira (adalimumab), is now available to patients in the United States after five years of experience in Europe and two years in Canada.
The company, which recently announced its acquisition of Viatris
